昆明市盘龙区台俪妇科医院昆明现在做流产价钱是多少,昆明哪个流产比较较好,哪里做人流安全昆明,昆明哪做人流做得好,昆明人流选哪家医院好,昆明那个医院看妇科,昆明怀孕七个月引产

BEIJING, Jan. 6 (Xinhua) -- China's railways will carry 235 million passengers during the 40-day Spring Festival travel rush, up 6.1 percent year-on-year, the Ministry of Railways said Friday.A daily average of 5.88 million people will make trains trips from Jan. 8 to Feb. 16, the ministry said in a statement on its website.Economic hubs such as Beijing, Guangzhou, Shanghai and Hangzhou and the inland provinces of Sichuan, Hubei, Jiangxi, Anhui and Hunan will see the most activity during the period, as millions of rural migrant workers and students head home for family reunions, according to the statement.The ministry has arranged for extra trains in anticipation of the rush, the statement said, but added that "the conflict remains between passenger demand and railway capacity."Railway authorities have long been under pressure to increase capacity and improve ticketing services, as many citizens find it extremely hard to secure a single ticket during major holidays.The ministry has begun allowing customers to book their tickets online or by phone to ease the ordeal of buying tickets. However, website glitches and the huge demand have rendered the new ways ineffective to many ticket buyers.The Spring Festival, or the Chinese Lunar New Year, falls on Jan. 23.

BEIJING, Jan. 14 (Xinhua) -- A Spring Festival gala was held at the Great Hall of the People Saturday to entertain the country's military officers, soldiers and civilians.Representatives of officers and soldiers in the military units and armed police forces in Beijing as well as some Beijing residents attended the gala.President Hu Jintao and other top Chinese leaders including Wu Bangguo, Jia Qinglin, Li Changchun, Xi Jinping, Li Keqiang, He Guoqiang and Zhou Yongkang were also present at the gala.Hu expressed greetings to the audience and extended his good wishes for them, ahead of the traditional Spring Festival, or the Chinese Lunar New Year, which falls on Jan. 23 this year.

BEIJING, Nov. 22 (Xinhuanet) -- Women aged 40 to 49 are not recommended for routine mammography screening for breast cancer, said the new guidelines issued by the Canadian Task Force on Preventive Health Care in media reports Tuesday.The new guidelines are purposed to direct doctors on using mammography, MRI scans, clinical breast exams and breast self-exams. In principle, they pointed out, there is no need for women to take clinical breast exams and breast self examination if there are no signals for breast cancer.Below are the main points from the guidelines which need special attention from women with reasonable doubt on the matter:Women aged 40-49 who have lower risk for cancer should not take routine mammography because of the higher risk for overdiagnosis, overtreatment and false-positives;Women aged 50 to 69 years and aged 70 to 74 years should go for routine screening every two to three years;And there should be no routine clinical breast exams by doctors and no breast self-exams to screen for breast cancer.Dr. Marcello Tonelli, Chair of the Task Force and Associate Professor at the University of Alberta, remarked: "The main effect of screening is to produce patients with breast cancer from among healthy women who would have remained free of breast disease for the rest of their lives had they not undergone screening.""The best method we have to reduce the risk of breast cancer is to stop the screening program," he added, "This could reduce the risk by one-third in the screened age group, as the level of overdiagnosis in countries with organized screening programs is about 50 percent."

BEIJING, Dec. 14 (Xinhua) -- Chinese President Hu Jintao on Wednesday exchanged congratulatory messages with Cypriot President Demetris Christofias on the 40th anniversary of bilateral diplomatic ties.In his message, Hu said bilateral ties between China and Cyprus have developed smoothly since they were established.Political mutual trust has continued to deepen and the two countries understand each other and support each other's major concerns, he said, adding bilateral pragmatic cooperation has also been expanding continuously.China highly values its relations with Cyprus and is ready to work with the country to deepen their traditional friendship, strengthen exchanges at various levels and enhance cooperation in such areas as economy, trade, culture and tourism, the Chinese president said.Hu said China is also willing to maintain communication and coordination with Cyprus on international and regional affairs.Christofias, for his part, said China and Cyprus have carried out close exchanges and cooperation, adding bilateral ties have been further strengthened through frequent high-level exchanges in recent years.Cyprus believes the two countries are on friendly terms and understand each other, which is in line with the common interests of both China and Cyprus, Christofias said.The president said Cyprus also believes bilateral relations would make further progress in the future.Chinese Foreign Minister Yang Jiechi also exchanged congratulatory messages on Wednesday with his Cypriot counterpart Erato Kozakou Marcoullis.

BEIJING, Oct. 11 (Xinhuanet) -- An experimental drug that can remove amyloid plaques from the brains of Alzheimer's patients is being developed by Swiss Roche Holding AG in a small early-stage study, according to a report published in the Archives of Neurology on Monday.Researchers suspect the build-up of such plaques may be a cause of the memory robbing disease, although that theory has yet to be definitively proved. Gantenerumab, a biotech drug designed to bind to amyloid plaques in the brain and remove them, is being targeted at the early stages of Alzheimer's with the hope it can slow progression of the disease while patients are still able to function.The Phase I study of 16 Alzheimer's patients tested gantenerumab at two doses against a placebo over six months of treatment.The Roche drug led to a dose-dependent reduction of brain amyloid, while amyloid load increased in patients receiving a placebo, the report said.The next step will be to investigate whether removal of brain amyloid translates into clinical benefit for patients at doses of the experimental drug that are well tolerated and safe, the report said.Much larger trials and further study will be needed to fully understand how gantenerumab works and whether it can stave off Alzheimer's, said the report.Roche is approaching the disease far earlier because amyloid accumulates for 15 years before dementi.